BR9908226A - Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo - Google Patents

Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo

Info

Publication number
BR9908226A
BR9908226A BR9908226-8A BR9908226A BR9908226A BR 9908226 A BR9908226 A BR 9908226A BR 9908226 A BR9908226 A BR 9908226A BR 9908226 A BR9908226 A BR 9908226A
Authority
BR
Brazil
Prior art keywords
fusion proteins
antibody
life
improvement
circulating half
Prior art date
Application number
BR9908226-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen D Gillies
Kin-Ming Lo
Yan Lan
John Wesolowski
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of BR9908226A publication Critical patent/BR9908226A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR9908226-8A 1998-02-25 1999-02-24 Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo BR9908226A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7588798P 1998-02-25 1998-02-25
PCT/US1999/003966 WO1999043713A1 (en) 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins

Publications (1)

Publication Number Publication Date
BR9908226A true BR9908226A (pt) 2000-10-24

Family

ID=22128576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908226-8A BR9908226A (pt) 1998-02-25 1999-02-24 Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo

Country Status (11)

Country Link
EP (1) EP1060194A1 (enrdf_load_stackoverflow)
JP (1) JP2002505086A (enrdf_load_stackoverflow)
CN (1) CN1204147C (enrdf_load_stackoverflow)
AU (1) AU758240B2 (enrdf_load_stackoverflow)
BR (1) BR9908226A (enrdf_load_stackoverflow)
CA (1) CA2320403A1 (enrdf_load_stackoverflow)
CZ (1) CZ20003099A3 (enrdf_load_stackoverflow)
HU (1) HUP0100813A3 (enrdf_load_stackoverflow)
NO (1) NO20004218L (enrdf_load_stackoverflow)
PL (1) PL199659B1 (enrdf_load_stackoverflow)
WO (1) WO1999043713A1 (enrdf_load_stackoverflow)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
NZ539776A (en) 1999-01-15 2006-12-22 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ES2256027T3 (es) 1999-08-09 2006-07-16 Emd Lexigen Research Center Corp. Complejos de anticuerpos que contienen multiples citoquinas.
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
MXPA02007733A (es) * 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
MXPA03009924A (es) 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
AU2003222664A1 (en) * 2002-04-18 2003-11-03 Genencor International, Inc. Production of functional antibodies in filamentous fungi
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CA2502904C (en) * 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DE60333121D1 (de) 2002-12-17 2010-08-05 Merck Patent Gmbh Pers 14.18, der gd2 bindet und seine fusion mit il-2
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
DK1699822T3 (da) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
CN1902222A (zh) 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9296816B2 (en) 2005-04-15 2016-03-29 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2007014278A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1919503B1 (en) 2005-08-10 2014-09-24 MacroGenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
AU2007281876B2 (en) 2006-06-26 2013-09-05 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP1873166B1 (en) * 2006-06-30 2010-09-08 CONARIS research institute AG Improved sgp 130Fc dimers
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
DK2219672T3 (en) 2007-11-09 2016-05-17 Peregrine Pharmaceuticals Inc The anti-VEGF antibody compositions and methods
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
AU2009231991B2 (en) 2008-04-02 2014-09-25 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
AU2010225951B2 (en) * 2009-03-19 2014-03-13 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
ES2548030T3 (es) 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
HRP20180574T1 (hr) 2009-10-07 2018-06-01 Macrogenics, Inc. Polipeptidi s područjem fc koji pokazuju poboljšanu efektornu funkciju zbog promjena u opsegu fukoziliranja, te postupci njihove upotrebe
IN2012DN05169A (enrdf_load_stackoverflow) 2009-12-02 2015-10-23 Acceleron Pharma Inc
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
RS59269B1 (sr) 2010-03-04 2019-10-31 Macrogenics Inc Antitela reaktivna na b7-h3, njihovi imunološki aktivni fragmenti i njihove upotrebe
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5964300B2 (ja) 2010-08-02 2016-08-03 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディおよびその使用
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
KR20130119948A (ko) 2010-11-23 2013-11-01 글락소 그룹 리미티드 온코스타틴 ｍ (ｏｓｍ)에 대한 항원 결합 단백질
CA2818621A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
MX2013007392A (es) 2010-12-22 2013-11-01 Cephalon Australia Pty Ltd Anticuerpo modificado con vida media mejorada.
JP5926791B2 (ja) 2011-03-29 2016-05-25 ロシュ グリクアート アーゲー 抗体Ｆｃ変種
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX347818B (es) 2011-05-21 2017-05-15 Macrogenics Inc Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
BR112014001855A2 (pt) 2011-07-27 2017-02-21 Glaxo Group Ltd construto e proteína aglutinantes ao antígeno, dímero, composição farmacêutica, sequência de polinucleotídeo, célula hospedeira e, método para produção do construto
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
EP3539982B1 (en) 2011-12-23 2025-02-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
ES2896493T3 (es) 2012-07-13 2022-02-24 Roche Glycart Ag Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
CN104508133B (zh) 2012-08-02 2018-04-20 弗·哈夫曼-拉罗切有限公司 用于产生单体和多聚体分子的方法及其用途
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
MX383596B (es) 2013-03-14 2025-03-14 Macrogenics Inc Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
LT3102595T (lt) 2014-02-06 2019-01-25 F. Hoffmann-La Roche Ag Interleukino-2 sulieti baltymai ir jų panaudojimas
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CN106573961B (zh) 2014-06-20 2022-01-04 豪夫迈·罗氏有限公司 基于chagasin的支架组合物、方法和应用
HUE051414T2 (hu) 2014-08-11 2021-03-01 Delinia Inc Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
CA2967820A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
RU2021133819A (ru) 2015-09-02 2021-12-10 Иммутеп С.A.С. Анти-lag-3 антитела
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
JP6794448B2 (ja) 2015-12-04 2020-12-02 ノバルティス アーゲー 抗体サイトカイングラフト組成物および免疫調節のための使用方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MX394519B (es) 2016-04-15 2025-03-24 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018049275A1 (en) 2016-09-09 2018-03-15 Genentech, Inc. Selective peptide inhibitors of frizzled
WO2018073365A1 (en) * 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
EP4512418A2 (en) 2018-08-31 2025-02-26 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
EP3929212A4 (en) * 2019-02-22 2022-11-23 Wuhan Yzy Biopharma Co., Ltd. MODIFIED FC FRAGMENT, ANTIBODY COMPRISING THEM AND THEIR APPLICATION
CA3146471A1 (en) 2019-08-06 2021-02-11 James K. Kranz Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
PE20221506A1 (es) * 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
CN117396513A (zh) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的联合疗法
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
EP4447969A1 (en) 2021-12-17 2024-10-23 VIIV Healthcare Company Combination therapies for hiv infections and uses thereof
CN119300858A (zh) 2022-04-29 2025-01-10 23和我公司 抗原结合蛋白
JP2025527672A (ja) 2022-08-25 2025-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびその使用
WO2024083945A1 (en) 2022-10-20 2024-04-25 Glaxosmithkline Intellectual Property (No.3) Limited Antigen binding proteins
KR20250099718A (ko) 2022-11-02 2025-07-02 비브 헬스케어 유케이 (넘버5) 리미티드 항원 결합 단백질
WO2025114862A1 (en) 2023-11-27 2025-06-05 Glaxosmithkline Intellectual Property Development Limited Il-33 binding antibodies
WO2025125137A1 (en) 2023-12-11 2025-06-19 Glaxosmithkline Intellectual Property Development Limited Baff specific antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
AU2527397A (en) * 1996-03-13 1997-10-01 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses

Also Published As

Publication number Publication date
HK1036286A1 (en) 2001-12-28
CZ20003099A3 (cs) 2002-04-17
HUP0100813A2 (hu) 2001-06-28
JP2002505086A (ja) 2002-02-19
PL199659B1 (pl) 2008-10-31
EP1060194A1 (en) 2000-12-20
NO20004218D0 (no) 2000-08-23
AU758240B2 (en) 2003-03-20
CN1204147C (zh) 2005-06-01
WO1999043713A1 (en) 1999-09-02
AU2784299A (en) 1999-09-15
NO20004218L (no) 2000-10-24
HUP0100813A3 (en) 2003-08-28
PL342497A1 (en) 2001-06-04
CA2320403A1 (en) 1999-09-02
CN1291995A (zh) 2001-04-18

Similar Documents

Publication Publication Date Title
BR9908226A (pt) Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
Qin et al. A comparative study of sialic acid‐rich proteins in rat bone and dentin
Südhof et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor
Stimmel et al. Site-specific conjugation on serine→ cysteine variant monoclonal antibodies
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
ATE489395T1 (de) Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
BR0314093A (pt) Proteìnas de fusão de transferrina modificada-anticorpo
DE60333306D1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
ATE366816T1 (de) Typ ii tgf-beta receptor/immunoglobulin konstante domäne fusionsproteine
PL1606318T3 (pl) Ulepszone białka fuzyjne FC
BR9712410A (pt) Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado
CY1109645T1 (el) Ανθρωπινος πρωτεϊνικος υποδοχεας τυπου toll, σχετικα αντιδραστηρια και μεθοδοι
DE69939897D1 (de) Entwicklung von menschlichen monoklonalen antikörpern und deren gebrauch
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
Failer et al. Determination of native oligomeric state and substrate specificity of rat NTPDase1 and NTPDase2 after heterologous expression in Xenopus oocytes
BR9810917A (pt) Polipeptìdeo isolado, proteìna de fusão, vetor de expressão, célula cultivada, processo para produzir um polipeptìdeo, composição farmacêutica, anticorpo, proteìna de ligação, polinucleotìdeo isolado, e, sonda de oligonucleotìdeo ou iniciador
DE69915320D1 (de) Immunoglobulin-bindende proteine
DE69535789D1 (de) Il-2r-assoziiertes polypeptid und dafür kodierende dna-molekülen
BRPI0511793A (pt) proteìnas quiméricas isoladas de lumazina sintase modificada
Matsuzawa et al. Identification of a receptor-binding domain of Bordetella dermonecrotic toxin
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
Koch et al. Association of surface IgM with two membrane proteins on murine B lymphocytes detected by chemical crosslinking
ATE286123T1 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
DK1539221T3 (da) Transferrin-fusionsproteinbiblioteker

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: EMD LEXIGEN RESEARCH CENTER CORP. (US)

Free format text: ALTERADO DE: LEXIGEN PHARMACEUTICALS CORP.

B25G Requested change of headquarter approved

Owner name: EMD LEXIGEN RESEARCH CENTER CORP. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO 020080150458 DE 05/12/2008

B25A Requested transfer of rights approved

Owner name: MERCK PATENT GMBH (DE)

Free format text: TRANSFERIDO DE: EMD LEXIGEN RESEARCH CENTER CORP.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.